cubes

Press Releases 2015

PsychoGenics Extends its Drug Discovery Collaboration with Sunovion

September 14, 2015 – TARRYTOWN, N.Y., – PGI Drug Discovery LLC (PsychoGenics), announced that the Company has extended its drug discovery and development collaboration with Sunovion Pharmaceuticals Inc. (Sunovion) for another four years. Read More.

PsychoGenics Obtains a License to Another Transgenic Mouse Model of α-Synucleinopathies

August 11, 2015 – TARRYTOWN, New York. – PsychoGenics announced that it has obtained a license from the University of California, San Diego School of Medicine to another α-synuclein transgenic mouse model known as Line 1, over-expressing human wild type α-synuclein under control of the MBP-promoter in oligodendrocytes. This model is a valuable tool to research the contribution of α-synuclein in the pathogenesis of multiple system atrophy (MSA). Read More.

PsychoGenics Obtains a License to α-synuclein Transgenic Mouse Models of Parkinson´s disease

March 18, 2015 – Tarrytown, N.Y., – PsychoGenics announced today that it has obtained a license from the University of California, San Diego School of Medicine to two of their α-synuclein transgenic mouse models, over-expressing human wild type α-synuclein under control of the PDGF-promoter and the murine Thy-1 promoter. Both models are established and accepted as extremely valuable tools to research the contribution of α-synuclein in the pathogenesis of Parkinson's disease. Read More.

Resilience and PsychoGenics Announce a Drug Discovery Partnership

March 2, 2015 – BOSTON, MA and TARRYTOWN, New York. – Resilience Therapeutics, Inc. (Resilience) and PGI Drug Discovery LLC (PsychoGenics), today announced that they have entered into a partnership to discover and optimize novel treatments for Post-Traumatic Stress Disorder (PTSD) and related conditions. Read More.

PsychoGenics Achieves Another Milestone in Drug Discovery Collaboration with Sunovion

January 27, 2015 – Tarrytown, New York. – PGI Drug Discovery LLC (PsychoGenics), today announced the achievement of a milestone in its drug discovery and development collaboration with Sunovion Pharmaceuticals Inc. Read More.

PsychoGenics Obtains a License to the McGill-R-Thy1-APP Rat Model of Alzheimer’s Disease

January 21, 2015 – Tarrytown, New York. – PsychoGenics announced today that it has obtained a license from McGill University (Montreal/Canada) to its McGill-R-Thy1-APP rat model of Alzheimer’s disease, expressing human APP with the Swedish (K670N/M671L) and Indiana (V717F) mutations under the control of the murine-Thy-1 promoter. Read More.

 

  • PsychoGenics
  • 215 College Road, Paramus, NJ 07652
  • Tel: (914) 406-8019
  • Fax: (914) 406-8090